Neurogenic Erectile Dysfunction. Where Do We Stand?

• Main Authors: Charalampos Thomas, Charalampos Konstantinidis
• Format: Article
• Language: English
• Published: MDPI AG 2021-01-01
• Series: Medicines
• Subjects: erectile dysfunction (ED); neurogenic; sexual dysfunction (SD); phosphodiesterase type-5 inhibitors (PDE5I); spinal cord injury (SCI); multiple sclerosis (MS)
• Online Access: https://www.mdpi.com/2305-6320/8/1/3

Erectile Dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance, causing tremendous effects on both patients and their partners. The pathophysiology of ED remains a labyrinth. The underlying mechanisms of ED may be vasculogenic, neurogenic, anatomical, hormonal, drug-induced and/or psychogenic. Neurogenic ED consists of a large cohort of ED, accounting for about 10% to 19% of all cases. Its diversity does not allow an in-depth clarification of all the underlying mechanisms nor a “one size fits all” therapeutical approach. In this review, we focus on neurogenic causes of ED, trying to elucidate the mechanisms that lie beneath it and how we manage these patients.